A literature review of ANK2‐related epilepsy demonstrates that the majority of patients (8 out of 10) have young‐onset (<6 years old) self‐limited focal epilepsy or neonatal seizure, which mostly respond well to ASM monotherapy. Here, ANK2 is linked to focal epilepsy.